While it’s hard to determine the incidence of meibomian gland dysfunction (MGD) in children, it can be a serious issue in this population. Two ophthalmologists discussed MGD in pediatric patients and what to look for.
Rosacea can be a significant problem for many patients and may be more prevalent than physicians think. Depending on the subtype, there may be ocular involvement. Three physicians discussed treatment strategies, in addition to sharing what to look for and how to diagnose.
EyeWorld Glaucoma Editor Nathan Radcliffe, MD, previews the articles in the Glaucoma section of the issue, specifically highlighting some of the advances and changes coming to the field.
While modern angle surgery has been a boon for patients and physicians wishing to avoid or delay more invasive glaucoma procedures and/or reduce the number of topical medications, cyclodialysis cleft, while rare, is still a complication that can occur.
In some glaucoma practices, selective laser trabeculoplasty (SLT) has become a mainstay option at various stages of disease and treatment. However, some ophthalmologists say that despite its diverse utility, SLT adoption has been slow in other practices, and a more recent advancement in related technology could increase adoption.
With many expanding technologies in ophthalmology, it makes sense that teaching modalities in the field would expand as well. Anuradha Khanna, MD, created the OcuSim virtual reality training, designed to be used specifically with the Oculus headset, to help teach some of the anatomy and knowledge needed in ophthalmic training.
Based on the authors’ experience in the field in practices around the world, this article offers a list of the basics for maintaining a better practice.
For ophthalmic practices to thrive in 2022, effective digital marketing strategies are a must. This article discusses a number of touchpoints every practice should consider when organizing and strategizing digital efforts.
It’s not the first time the trigeminal nerve pathway or even intranasal delivery received approval as a treatment for dry eye, but clinicians are excited nonetheless about the October 2021 FDA approval of varenicline (TYRVAYA, Oyster Point Pharma), a nasal spray for the signs and symptoms of dry eye disease.